XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.15

+2.8%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Thomas J Pittman who wrote (3915)	9/25/1997 5:09:00 PM
From: tom jones	of 17367

J, Robert and all: Yes I do see neuprex for meningococcemia as being marginal and I think it will be very hard for this drug to pass food and drug if it remains marginal. I have no idea (repeat, no idea) if Xoma's BPI is working and that is why I would like to see their phase II results. They have finished phase I/II trial for meningococcemia and phase II trial for hemorrhagec trauma and ending phase II for partial hepatectomy. I listen to McCamant and Murry only because this type data is not available thinking they may know something which is probably not right and I read the Xoma board and do think most of you do know something. Information is the key to the highway. Tom

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next